BRPI0409497A - métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite - Google Patents

métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite

Info

Publication number
BRPI0409497A
BRPI0409497A BRPI0409497-2A BRPI0409497A BRPI0409497A BR PI0409497 A BRPI0409497 A BR PI0409497A BR PI0409497 A BRPI0409497 A BR PI0409497A BR PI0409497 A BRPI0409497 A BR PI0409497A
Authority
BR
Brazil
Prior art keywords
methods
diagnosis
treatment
tyrosine kinases
relates
Prior art date
Application number
BRPI0409497-2A
Other languages
English (en)
Inventor
Sherif Daouti
Brian Jude Latario
Chandrika Saidapet Kumar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0409497A publication Critical patent/BRPI0409497A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODOS E COMPOSIçõES QUE ALVEJAM TIROSINA CINASES PARA A DIAGNOSE E TRATAMENTO DE OSTEOARTRITE". A presente invenção refere-se aos membros de uma subfamília de receptor tirosina cinases compreendendo TYRO3, Axl, cMer e ligantes dos mesmos, como GAS6 que são alvos adequados para o desenvolvimento de novas terapias para tratar, impedir ou melhorar OA. A invenção também refere-se aos métodos para tratar e/ou melhorar OA e composições farmacêuticas dos mesmos compreendendo moduladores com efeito inibidor na expressão ou atividade dos membros da mesma subfamília de receptores tirosina e ligantes relacionados. A invenção também refere-se a um método para identificar compostos com utilidade terapêutica para tratar OA, compreendendo identificar compostos que podem, por exemplo, inibir a atividade e/ou expressão dos mesmos polipeptídeos.
BRPI0409497-2A 2003-04-18 2004-04-16 métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite BRPI0409497A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46393503P 2003-04-18 2003-04-18
PCT/EP2004/004052 WO2004092735A2 (en) 2003-04-18 2004-04-16 Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
BRPI0409497A true BRPI0409497A (pt) 2006-05-02

Family

ID=33300099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409497-2A BRPI0409497A (pt) 2003-04-18 2004-04-16 métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite

Country Status (9)

Country Link
US (1) US20070142273A1 (pt)
EP (1) EP1618385A2 (pt)
JP (1) JP2006524496A (pt)
CN (1) CN1774634A (pt)
AU (2) AU2004231036A1 (pt)
BR (1) BRPI0409497A (pt)
CA (1) CA2522984A1 (pt)
MX (1) MXPA05011171A (pt)
WO (1) WO2004092735A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102456A1 (en) 2004-03-27 2005-11-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
WO2007006808A1 (en) * 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
US8663930B2 (en) 2009-04-01 2014-03-04 Galapagos Nv Methods and means for treatment of osteoarthritis
ES2632345T3 (es) * 2010-01-22 2017-09-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibición de la señalización AXL en terapia antimetastásica
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
WO2014018535A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
ES2665323T7 (es) 2012-12-14 2023-06-15 Univ Leland Stanford Junior Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
US10894075B2 (en) * 2013-03-15 2021-01-19 GLAdiator Biosciences, Inc. Gla domains as targeting agents
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
CN113777312B (zh) * 2021-09-03 2024-02-02 普十生物科技(北京)有限公司 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用
WO2024054793A1 (en) 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2142317T3 (es) * 1991-07-02 2000-04-16 Scripps Research Inst Polipeptidos de proteinas s y uso de los mismos.
FI956352L (fi) * 1993-06-30 1996-02-28 Univ Leiden Proteiini S:n deleetiovariantteja, joilta puuttuu C4BP:tä sitova aktiivisuus mutta joilla on APC-kofaktoriaktiivisuus koostumuksia ja terapeuttisia menetelmiä
CA2175893C (en) * 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
US20040265808A1 (en) * 2001-04-05 2004-12-30 Teresa Garcia Genes involved in osteogenesis, and methods of use
JP2003012541A (ja) * 2001-06-07 2003-01-15 Daiichi Fine Chemical Co Ltd 血管新生阻害剤
US20040157774A1 (en) * 2002-09-24 2004-08-12 Jing Yang Epitope-tagged recombinant Growth Arrest Specific Gene 6 protein

Also Published As

Publication number Publication date
AU2004231036A1 (en) 2004-10-28
US20070142273A1 (en) 2007-06-21
WO2004092735A2 (en) 2004-10-28
CA2522984A1 (en) 2004-10-28
EP1618385A2 (en) 2006-01-25
CN1774634A (zh) 2006-05-17
JP2006524496A (ja) 2006-11-02
MXPA05011171A (es) 2005-12-14
WO2004092735A3 (en) 2005-03-17
AU2008202807A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
Singh et al. Role of Epigenetics on Synaptic Plasticity in Neurodegenerative Disorders
BR112021017430A2 (pt) Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos
Vaillancourt et al. Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis
BRPI0409497A (pt) métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite
Nelson et al. Neuroprotective versus tumorigenic protein kinase C activators
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
Jiang et al. Glucosamine protects nucleus pulposus cells and induces autophagy via the mTOR‐dependent pathway
Daily et al. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways
Kim et al. LIM kinase-2 induces programmed necrotic neuronal death via dysfunction of DRP1-mediated mitochondrial fission
Jaime‐Ramirez et al. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide
Sanli et al. Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival
Sun et al. Post-translational modifications of p65: state of the art
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI1013546A2 (pt) usos de um inibidor da timidilato sintase e de uma terapia anticâncer
Cortese et al. Carnosic acid induces proteasomal degradation of Cyclin B1, RB and SOX2 along with cell growth arrest and apoptosis in GBM cells
BRPI0406834A (pt) Tratamento de doença com agonistas totais do receptor nach alfa-7
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
Tezil et al. IKK-β mediates chemoresistance by sequestering FOXO3; a critical factor for cell survival and death
BRPI0518013A (pt) inibidores de proteìna tirosina fosfatase, composição farmacêutica, complexo e métodos de uso dos mesmos
Wang et al. Arbutin suppresses osteosarcoma progression via miR‐338‐3p/MTHFD1L and inactivation of the AKT/mTOR pathway
Singhatanadgit et al. Geranylgeraniol prevents zoledronic acid-mediated reduction of viable mesenchymal stem cells via induction of Rho-dependent YAP activation
He et al. Nocardamine mitigates cellular dysfunction induced by oxidative stress in periodontal ligament stem cells
Nilsson et al. Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells
John et al. Effects of quercetin and derivatives on NAMPT/Sirtuin-1 metabolic pathway in neuronal cells: an approach to mitigate chemotherapy-induced cognitive impairment
Ogunsuyi et al. Effect of curcumin–donepezil combination on spatial memory, astrocyte activation, and cholinesterase expressions in brain of scopolamine-treated rats

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.